TransMedics Group (TMDX) News Today

TransMedics Group (NASDAQ:TMDX) Shares Down 2.3%

TransMedics Group (NASDAQ:TMDX) Hits New 12-Month High at $155.74

Blair William & Co. IL lifted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 15.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 183,524 shares of the company's stock after purchasing an additional 24,417 shares during th

BNP Paribas Financial Markets increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 35.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,390 shares of the company's stock after ac

Morgan Stanley raised their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an "equal weight" rating in a report on Monday.

Oppenheimer & Co. Inc. increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 156.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,570 shares of the company's stock after purchasing an a

Lisanti Capital Growth LLC decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 46.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 58,495 shares of the company's stock after selling 50,940 s

TransMedics Group (NASDAQ:TMDX) Trading Down 5.6%

TransMedics Group (NASDAQ:TMDX) Sets New 1-Year High at $154.95

Principal Financial Group Inc. trimmed its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 63.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,980 shares of the company's stock after selling 1

Baillie Gifford & Co. trimmed its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 1.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 303,162 shares of the company's stock after selli

Vanguard Group Inc. lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,865,115 shares of the company's stock

Wasatch Advisors LP bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 434,971 shares of the company's stock, valued at approximately $32,162,000. Wasatch Adviso

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have assigned a buy ra

TransMedics Group (NASDAQ:TMDX) Reaches New 12-Month High at $152.31

Goldman Sachs Group Inc. raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 397,283 shares of the company's stock aft

Piper Sandler reiterated an "overweight" rating and issued a $120.00 price objective on shares of TransMedics Group in a research report on Friday.

HighPoint Advisor Group LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 7,640 shares of the company's stock, valued at

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) CEO Waleed H. Hassanein sold 8,625 shares of the business's stock in a transaction on Friday, June 14th. The shares were sold at an average price of $141.85, for a total transaction of $1,223,456.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at $8,744,059.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Osterweis Capital Management Inc. grew its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 78.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 64,565 shares of the company's stock after buying an additional 28,3

TransMedics Group (NASDAQ:TMDX) Shares Down 2.3%

First Light Asset Management LLC lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 22.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 754,317 shares of the company's st

Bellevue Group AG reduced its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 518,890 shares of the company's stock

TransMedics Group (NASDAQ:TMDX) Sets New 52-Week High on Analyst Upgrade

TransMedics Group (NASDAQ:TMDX) Shares Gap Up to $133.02

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have been given an average rating of "Moderate Buy" by the ten ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating

Cantor Fitzgerald initiated coverage on shares of TransMedics Group in a research note on Thursday. They issued an "overweight" rating and a $161.00 price objective on the stock.

Hsbc Holdings PLC boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 19.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,650 shares of the company's stock after

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) CFO Stephen Gordon sold 2,060 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $135.93, for a total transaction of $280,015.80. Following the completion of the transaction, the chief financial officer now directly owns 21,299 shares of the company's stock, valued at approximately $2,895,173.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

TransMedics Group (NASDAQ:TMDX) Trading Up 3.7%

Stephens initiated coverage on shares of TransMedics Group in a research report on Tuesday. They set an "overweight" rating and a $151.00 price objective for the company.

Alberta Investment Management Corp cut its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 30.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,752 shares of the company's stock after selling 6,137

Alpha DNA Investment Management LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 6,337 shares of the company's stock, valued at approximately $